What the recent move in BrightSpring Health Services (BTSG) means for investors

BrightSpring Health Services (BTSG) has recently drawn attention after a strong run in the stock over the past month and past 3 months, prompting investors to reassess how its current valuation lines up with its fundamentals.

The recent strength in BrightSpring Health Services’ stock, with a 30 day share price return of 20.67% and a 90 day share price return of 33.42%, sits on top of a 1 year total shareholder return of 135.08%. This indicates that momentum has been building around the current US$52.94 share price.

If you are looking for more ideas in healthcare and AI, this is a good moment to broaden your watchlist with 35 healthcare AI stocks

With BrightSpring trading at US$52.94 alongside an indicated intrinsic discount of 63% and some headroom to analyst targets, investors may want to consider whether the stock is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 11.2% Undervalued

BrightSpring’s most followed narrative pegs fair value at $59.60, above the latest $52.94 close, which puts the recent share price surge into sharper context.

Ongoing investments in integrated service delivery, technology, procurement, and automation are enabling enhanced operating efficiencies and cross-selling, expected to deliver sustained improvements in net margins and EBITDA through 2026 and beyond.

Want to see what sits behind that margin story? The narrative leans on a specific mix of revenue growth, earnings expansion and a forward profit multiple that might surprise you.

The fair value estimate is built using a 7.11% discount rate, detailed revenue and earnings forecasts, and an assumed profit margin step up over time rather than a one off jump.

Result: Fair Value of $59.60 (UNDERVALUED)

However, the story can change quickly if acquisition integrations fall short or if labor and wage pressures squeeze the thin US$171.041m net income base.

Another way to look at valuation

While the narrative points to an 11.2% undervaluation using future earnings and a fair P/E of 26.8x, the current P/E of 63.7x is much higher than both the US Healthcare average of 22.4x and a fair ratio of 34.8x. That gap raises a simple question: is the story running ahead of the numbers?

Next Steps

The mix of optimism and concern around BrightSpring is clear. This is a good time to review the key data yourself and move quickly to your own view with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Use this momentum to widen your watchlist, compare different opportunities, and pressure test your thesis across multiple angles.

• Target potential upside by scanning for underpriced quality using the 51 high quality undervalued stocks.
• Prioritize stability and sleep better at night by checking companies in the 72 resilient stocks with low risk scores.
• Hunt for tomorrow's standouts before the crowd catches on with the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.